临床研究
Copyright ©The Author(s) 2021.
世界华人消化杂志. 2021-04-08; 29(7): 347-355
在线出版 2021-04-08. doi: 10.11569/wcjd.v29.i7.347
表1 结直肠进展期腺瘤单因素比较
项目观察组
对照组
统计值P
n = 295n = 448
性别
175 (59.3%)230 (51.3%)4.5710.033
120 (40.7%)218 (48.7%)
年龄(岁)
62.5±10.856.7±11.76.9230.000
吸烟史
104 (35.3%)106 (23.7%)11.7920.001
191 (64.7%)342 (76.3%)
饮酒史
84 (28.5%)132 (29.5%)0.0840.771
211 (71.5%)316 (70.5%)
糖尿病
54 (18.3%)36 (8.0%)17.6210.000
241 (81.7%)412 (92.0%)
高血压
121 (41.0%)122 (27.2%)15.3570.000
174 (59.0%)326 (72.8%)
冠心病
41 (13.9%)34 (7.6%)7.8010.005
254 (86.1%)414 (92.4%)
阑尾切除史
29 (9.8%)53 (11.8%)0.7250.395
266 (90.2%)395 (88.2%)
胆囊切除史
19 (6.4%)4 (0.9%)18.2500.000
276 (93.6%)444 (99.1%)
IFOBT
(+)102 (34.6%)26 (5.8%)109.1500.000
(-)193 (65.4%)422 (94.2%)
CEA (ng/mL)2.40 (1.52, 3.64)2.05 (1.38, 3.07)9.3010.003
CA199 (U/mL)8.17 (4.84, 14.72)5.74 (3.45, 9.89)41.0770.000
NLR2.46±1.511.77±0.767.1600.000
PLR125.37±53.61119.51±38.801.7010.090
表2 结直肠进展期腺瘤Logistic回归分析
项目B值SEWaldPOR95%CI
性别0.2810.1942.1030.1471.3240.096-1.936
年龄0.0450.00923.8050.0001.0471.028-1.066
吸烟史0.6310.2089.1960.0021.8801.250-2.826
糖尿病0.7290.2727.1700.0072.0731.216-3.535
高血压0.3040.1972.3870.1221.3550.922-1.992
冠心病0.3010.2991.0140.3141.3520.752-2.431
胆囊切除2.2200.58914.2240.0009.2062.904-29.181
IFOBT2.0390.26359.9580.0007.6814.585-12.869
CEA0.0110.0480.0560.8131.0110.920-1.112
CA1990.0380.01014.2680.0001.0391.018-1.059
NLR-0.0020.0021.0170.0001.7061.388-2.097
表3 粪便免疫潜血实验、CA199、中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值单指标及联合检测对结直肠进展期腺瘤的诊断价值
项目灵敏度(%)特异度(%)AUC95%CIP
IFOBT34.694.20.6440.602-0.6860.000
CA19953.966.10.6390.598-0.6790.000
NLR50.271.80.6450.605-0.6850.000
联合52.982.80.7520.716-0.7880.000
表4 不同临床特征进展期腺瘤中粪便免疫潜血实验、CA199、中性粒细胞/淋巴细胞比值水平的比较
项目例数IFOBT(-)
IFOBT(+)
P低CA199
高CA199
P低NLR
高NLR
P
(n = 193)(n = 102)(n = 136)(n = 159)(n = 147)(n = 148)
年龄(岁)0.2470.4460.101
<5032171517151220
50-5971452636353734
60-69118774154646751
≥7074542029453143
性别0.3840.5810.004
120823853677248
17511164839275100
腺瘤位置0.0480.1320.503
近端结肠91672436554843
远端结肠2041267810010499105
腺瘤直径0.0000.2200.028
<10 mm4842625232820
10-19 mm143994470737865
≥20 mm104525241634163
病理类型0.3550.9800.078
TA100693146545743
TVA+VA195124719010590105
分化级别0.0000.8630.000
低级别214153619811611193
高级别81404138433655

引文著录: 王绪, 张竞宇, 郑忠青, 王涛, 朴美玉, 刘恒, 刘静, 刘文天. IFOBT与肿瘤标志物、炎症指标联合检测对结直肠进展期腺瘤发生的预测价值. 世界华人消化杂志 2021; 29(7): 347-355